Dr. Martens (LON:DOCS) Earns “Buy” Rating from Berenberg Bank

Dr. Martens (LON:DOCS)‘s stock had its “buy” rating reissued by stock analysts at Berenberg Bank in a research note issued to investors on Tuesday, MarketBeat Ratings reports.

Separately, Peel Hunt reissued a “buy” rating on shares of Dr. Martens in a research report on Thursday, November 20th. Two analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of GBX 6,000.

Dr. Martens Trading Down 1.8%

LON DOCS opened at GBX 65.70 on Tuesday. The firm has a market capitalization of £635.03 million, a P/E ratio of 38.65, a PEG ratio of 6.40 and a beta of 0.11. The business has a fifty day simple moving average of GBX 75.88 and a 200 day simple moving average of GBX 83.26. Dr. Martens has a 12 month low of GBX 43.02 and a 12 month high of GBX 100.87. The company has a current ratio of 2.85, a quick ratio of 1.13 and a debt-to-equity ratio of 127.27.

Dr. Martens (LON:DOCS) last posted its quarterly earnings data on Thursday, November 20th. The company reported GBX (0.90) earnings per share (EPS) for the quarter. Dr. Martens had a return on equity of 18.91% and a net margin of 7.89%. On average, analysts predict that Dr. Martens will post 2.5809394 EPS for the current fiscal year.

Insider Buying and Selling at Dr. Martens

In related news, insider Robert Hanson purchased 96,000 shares of Dr. Martens stock in a transaction that occurred on Friday, December 5th. The stock was bought at an average price of GBX 79 per share, for a total transaction of £75,840. Over the last quarter, insiders have bought 97,130 shares of company stock valued at $7,673,816. 2.79% of the stock is currently owned by insiders.

More Dr. Martens News

Here are the key news stories impacting Dr. Martens this week:

• Positive Sentiment: Berenberg reaffirmed a “buy” rating on DOCS, giving investors a broker-level vote of confidence that could support the stock if sentiment stabilizes. Berenberg buy rating
• Neutral Sentiment: Management now expects flat revenue for 2026 as Dr. Martens scales back promotional activity to protect margins — this signals a shift toward margin discipline but also warns of limited near-term top-line growth. Dr Martens projects flat 2026 revenue
• Negative Sentiment: Reports say demand has softened and sales have slowed, attributing part of the weakness to fewer discounts deterring price-sensitive shoppers — evidence that reduced promotions are hurting volume more than boosting margin so far. Dr. Martens shares take a kicking after demand falls
• Negative Sentiment: Additional coverage highlights boot sales slowing as fewer discounts deter shoppers — reinforces the view that promotional pullback is pressuring volumes and near-term revenue. Dr Martens boot sales slow as fewer discounts deter shoppers

About Dr. Martens

Founded in 1960, Dr. Martens is an iconic British brand with a global presence. “Docs” or “DMs” were originally
produced for their durability for workers, before being adopted by diverse youth subcultures and associated musical
movements. Today, Dr. Martens has transcended its roots while still celebrating its proud history. It operates in over
60 countries and employs over 3,650 people worldwide. Its operations are split across both Direct-to-Consumer and
wholesale channels, and in addition to its world-renowned “1460” boot its product segments span shoes including the
1461 shoe and Adrian loafer, sandals including the Zebzag mule, Kids ranges, as well as a growing line of bags and
accessories.

The Company successfully listed on the main market of the London Stock Exchange on 29 January 2021 (DOCS.L) and
is a constituent of the FTSE 250 index.